Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Twin Momentum Investor model based on the published ...

To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future". For the year to March 2025, Gilead Sciences had an accrual ratio of -0.11.

Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Twin Momentum Investor model based on the published ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences shareholders are no doubt pleased ... This is what you'd expect to see where a company has a non-cash charge reducing paper profits. It's never great to see unusual items costing ...

Gilead Sciences is a California-based biopharmaceutical company with a $95 billion market cap, known for its treatments in HIV, hepatitis B, hepatitis C, and cancer. In Q2 2023, Gilead Sciences ...

Biktarvy maintained HIV-1 suppression in 95.4% and HBV suppression in 86.6% of participants after 96 weeks of treatment switch. Lenacapavir with teropavimab and zinlirvimab showed 96% virologic ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while ...